-
-
Overview
-
Please contact us at for specific academic pricing.
Background
SB 204990 is a specific inhibitor of ATP citrate lyase (ACLY) enzyme.
In HepG2 cells, SB 204990 inhibits fatty acid and cholesterol synthesis in a concentration-dependent manner. Oral administration of SB 204990 (25 mg/kg) reduces plasma levels of the lipoproteins VLDL, LDL, and HDL by 21, 40, and 22%, respectively, in dogs. It also reduces VLDL synthesis and plasma cholesterol and triglyceride levels in rats in a dose-dependent manner.
-
- Properties
-
Overview